AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).
Honeywell (Nasdaq: HON) today announced key leadership roles for its Advanced Materials business, which will be named Solstice Advanced Materials after its tax-free spin to shareholders targeted to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback